CASI Pharmaceuticals (FRA:ENM) Current Accrued Expense : €7.32 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Current Accrued Expense?

CASI Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2024 was €7.32 Mil.

CASI Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2023 (€8.68 Mil) to Dec. 2023 (€0.49 Mil) but then increased from Dec. 2023 (€0.49 Mil) to Mar. 2024 (€7.32 Mil).

CASI Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2021 (€0.05 Mil) to Dec. 2022 (€0.61 Mil) but then declined from Dec. 2022 (€0.61 Mil) to Dec. 2023 (€0.49 Mil).

CASI Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for CASI Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Current Accrued Expense Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

2.55

0.04

0.05

0.61

0.49

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															9.84	8.80	8.68	0.49	7.32

CASI Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

CASI Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines